Original language | English |
---|---|
Pages (from-to) | 1726-1730 |
Number of pages | 5 |
Journal | Haematologica |
Volume | 107 |
Issue number | 7 |
DOIs | |
Publication status | Published - 1 Jul 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Haematologica, Vol. 107, No. 7, 01.07.2022, p. 1726-1730.
Research output: Contribution to journal › Letter › Academic › peer-review
TY - JOUR
T1 - Treatment emergent peripheral neuropathy in the CASSIOPEIA trial
AU - Fokkema, Cathelijne
AU - Moreau, Phillipe
AU - van der Holt, Bronno
AU - Lambert, J. rôme
AU - van Duin, Mark
AU - Wester, Ruth
AU - Jongen, Joost L. M.
AU - van Doorn, Pieter A.
AU - Godet, Sophie
AU - Jie, KonSiong
AU - Fitoussi, Olivier
AU - Delforge, Michel
AU - Keita-Manta, Awa
AU - Luycx, Odile
AU - Cupedo, Tom
AU - van de Donk, Niels W. C. J.
AU - Zweegman, Sonja
AU - Vermeulen, Jessica T.
AU - Sonneveld, Pieter
AU - Broijl, Annemiek
N1 - Funding Information: PM receives honoraria from AbbVie, Amgen, Celgene, Janssen, and Takeda, is a member of AbbVie's, Amgen's, Celgene's, Janssen Pharmaceuticals', and Takeda's Board of Directors or advisory committees, and is a member of AbbVie's, Amgen's, Celgene's, and Janssen Pharmaceuticals Speakers Bureau. JL is employed by Janssen Pharmaceuticals. JJ received honoraria from Amgen and Mundipharma. MD received speaker honoraria from Amgen, BMS Celgene, Janssen, Takeda, Sanofi. NWCJvdD is a consultant for Amgen, Bayer, Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, Novartis, Servier, and Takeda and receives research funding from Amgen, Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, and Novartis. SZ receives research funding from and is a member of the Board of Directors or advisory committees for Celgene, Janssen Pharmaceuticals, and Takeda. JV is employed by and owns equity in Janssen Pharmaceuticals. PS receives honoraria and research funding from Amgen, Celgene, Janssen Pharmaceuticals, Karyopharm, and Takeda and receives researching funding from Skyline. AB receives honoraria from Amgen, Bristol-Myers Squibb, Celgene, and Janssen Pharmaceuticals. All other authors declare no competing interests. Funding Information: This study was supported by Intergroupe Francophone du Myélome (IFM), the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) in collaboration with Janssen Research & Development and the Dutch Cancer Society (KWF).
PY - 2022/7/1
Y1 - 2022/7/1
UR - http://www.scopus.com/inward/record.url?scp=85133356705&partnerID=8YFLogxK
U2 - https://doi.org/10.3324/haematol.2021.280567
DO - https://doi.org/10.3324/haematol.2021.280567
M3 - Letter
C2 - 35295081
SN - 0390-6078
VL - 107
SP - 1726
EP - 1730
JO - Haematologica
JF - Haematologica
IS - 7
ER -